IDA-FLAG—An Effective Reinduction Therapy for Poor Prognosis AML of Childhood—Report of a Multicenter Phase II Trial
作者： G. Fleischhack , C. Hassan , N. Graf , G. Mann , U. Bode
DOI: 10.1007/978-3-642-18156-6_87
关键词:
摘要: The prognosis of refractory, relapsed or secondary AML is poor and effective reinduc tion regimens are rare. Allogeneic autolo gous bone marrow transplantation (BMT ABMT) offers a chance for long-term survival in these cases. Thus, phase II trial com bination therapy with fludarabine, HD-ARA C, idarubicin G-CSF was designed to study the feasibility efficacy treatment childhood as possible option prior BMT ABMT.
springer.com
sci-hub.st 参考文章(33)
RP Gale, MM Horowitz, JK Rees, RG Gray, MM Oken, EH Estey, KM Kim, MJ Zhang, RC Ash, K Atkinson, RE Champlin, KA Dicke, JL Gajewski, JM Goldman, W Helbig, PS Henslee-Downey, W Hinterberger, N Jacobsen, A Keating, JP Klein, AM Marmont, HG Prentice, J Reiffers, AA Rimm, MM Bortin, None, Chemotherapy versus transplants for acute myelogenous leukemia in second remission. Leukemia. ,vol. 10, pp. 13- 19 ,(1996)
H Gadner, D Niethammer, G Dini, J M Vossen, M Miano, L Manfredini, G Souillet, J M Cornish, P Paolucci, Bone marrow transplant indications for childhood leukemias: achieving a consensus. The EBMT Pediatric Diseases Working Party Bone Marrow Transplantation. pp. 4- 7 ,(1996)
Varsha Gandhi, V. Gregoire, Peng Huang, E. Estey, L. E. Robertson, Li-Ying Yang, W. Plunkett, M. J. Keating, Fludarabine : pharmacokinetics, mechanisms of action, and rationales for combination therapies Seminars in Oncology. ,vol. 20, pp. 2- 12 ,(1993)
Visani G, Ottaviani E, Zinzani Pl, Tosi P, Manfori S, Tura S, Fludarabine + Ara-C + G-CSF: cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells. Leukemia. ,vol. 8, pp. 2076- 2082 ,(1994)
Steven M. Kornblau, Elihu Estey, Jorge Cortes-Franco, Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia. Leukemia. ,vol. 7, pp. 378- 383 ,(1993)
A Heinecke, C M Sauerland, W R Martin, T Büchner, W Hiddemann, Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy. Leukemia. ,vol. 4, pp. 184- 188 ,(1990)
M. Keating, H. Kantarjian, V. Gandhi, S. O’Brien, C. Koller, S. Kornblau, M. Beran, M. Andreeff, W. Plunkett, E. Freireich, FLAG-Ida, an Effective Regimen for High Risk AML Springer, Berlin, Heidelberg. pp. 828- 833 ,(1998) , 10.1007/978-3-642-71960-8_112
G Visani, P Tosi, PL Zinzani, S Manfroi, E Ottaviani, N Testoni, M Clavio, A Cenacchi, B Gamberi, P Carrara, None, FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias. Leukemia. ,vol. 8, pp. 1842- 1846 ,(1994)
Ian M. Hann, Richard F. Stevens, Anthony H. Goldstone, John K.H. Rees, Keith Wheatley, Richard G. Gray, Alan K. Burnett, Randomized Comparison of DAT Versus ADE as Induction Chemotherapy in Children and Younger Adults With Acute Myeloid Leukemia. Results of the Medical Research Council's 10th AML Trial (MRC AML10) Blood. ,vol. 89, pp. 2311- 2318 ,(1997) , 10.1182/BLOOD.V89.7.2311
Peter P. Eckstein, SPSS für Windows Gabler Verlag. pp. 1- 12 ,(1997) , 10.1007/978-3-322-93157-3_1